Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Interleukin 12: still a promising candidate for tumor immunotherapy?

Author information

Affiliations

  • 1. Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, Banacha 1a, "F" Bldg, 02-097, Warsaw, Poland,
      Authors
    • Lasek W 1
    (1 author)

ORCIDs linked to this article

Cancer Immunology, Immunotherapy : CII, 11 Feb 2014, 63(5):419-435
https://doi.org/10.1007/s00262-014-1523-1 PMID: 24514955 PMCID: PMC3994286

Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Abstract 

Interleukin 12 (IL-12) seemed to represent the ideal candidate for tumor immunotherapy, due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities. However, despite encouraging results in animal models, very modest antitumor effects of IL-12 in early clinical trials, often accompanied by unacceptable levels of adverse events, markedly dampened hopes of the successful use of this cytokine in cancer patients. Recently, several clinical studies have been initiated in which IL-12 is applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies). The near future will show whether this renewed interest in the use of IL-12 in oncology will result in meaningful therapeutic effects in a select group of cancer patients.

Free full text 

Page not available

Reason: The web page address (URL) that you used may be incorrect.
URL: http://www.ebi.ac.uk/europepmc/ppmc/articles/PMC3994286/
Message ID: 535122813 (wp-p2m-39.ebi.ac.uk)
Time: 2024/11/20 11:24:50

If you need further help, please send an email to PMC. Include the information from the box above in your message.

Otherwise, click on one of the following links to continue using PMC:

  • Search the complete PMC archive.
  • Browse the contents of a specific journal in PMC.
  • Find a specific article by its citation (journal, date, volume, first page, author or article title).

Full text links 

Read article at publisher's site: https://doi.org/10.1007/s00262-014-1523-1

Read article for free, from open access legal sources, via Unpaywall: https://link.springer.com/content/pdf/10.1007/s00262-014-1523-1.pdfUnpaywall

Citations & impact 

Impact metrics

259
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2312611
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2312611

Article citations

Go to all (259) article citations

Data 

Data behind the article

This data has been text mined from the article, or deposited into data resources.

BioStudies: supplemental material and supporting data

Clinical Trials (Showing 7 of 7)

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.